Compounded GLP-1 Ban 2026: What's Still Legally Available

By April 2026, the FDA has fully removed semaglutide and tirzepatide from its drug shortage list and is closing the enforcement window that previously allowed compounded copies under 503A and 503B authority. Outsourcing facilities and 503A pharmacies that continued compounding GLP-1 receptor agonists outside narrow medical-necessity exceptions face warning letters, injunctions, and product seizures.

This is the culmination of a multi-year contest between manufacturers, compounders, telehealth platforms, and the agency. The April-May 2026 window marks the first sustained, broad enforcement push specifically targeting compounded GLP-1 distribution at consumer scale.

Section 503A of the Federal Food, Drug, and Cosmetic Act authorizes traditional compounding pharmacies to prepare individualized medications for identified patients with valid prescriptions. Section 503B governs outsourcing facilities that may compound at larger scale under more stringent quality requirements.

Neither pathway authorizes mass production of patentable, commercially available drug products. Both pathways require the active ingredient to be either an FDA-approved drug, on the 503A bulks list, or, in the case of 503B, on the 503B bulks list. Shortage-list drugs occupy a separate temporary exception that has now closed for semaglutide and tirzepatide.

• Compounded semaglutide preparations marketed as alternatives to Ozempic, Wegovy, or Rybelsus
• Compounded tirzepatide preparations marketed as alternatives to Mounjaro or Zepbound
• Add-mixture combinations of GLP-1 agonists with vitamins, glycine, or B12 designed to circumvent the bulks list
• Bulk distribution of compounded GLP-1 product to telehealth platforms operating without individualized clinical encounters
• Marketing of compounded GLP-1 products as equivalent to or interchangeable with branded drugs

Several lawful supply channels remain. FDA-approved branded GLP-1 products continue to be sold through manufacturer programs and retail pharmacies. Patients with documented medical necessity may still receive limited compounded preparations under tightly defined 503A clinical exceptions. New oral formulations and adjacent classes remain in active development.

Separately, research-grade reference material for laboratory use continues to circulate through peptide chemistry suppliers. This material is not a substitute for clinical care and is not lawful for human use under any framework.

Telehealth platforms that built business on compounded semaglutide or tirzepatide are repositioning. The most credible operators have shifted to FDA-approved branded GLP-1 prescribing, often paired with manufacturer savings programs, while less credible operators have closed or pivoted to non-GLP-1 weight management protocols.

Patients should be cautious of platforms that continue to promise compounded GLP-1 access at sub-branded pricing in mid-2026. The economics no longer support such offerings under lawful supply, and continued operation typically signals either narrow exception abuse or outright non-compliance.

Oral semaglutide is approved as Rybelsus for type 2 diabetes. Higher-dose oral formulations and oral candidates from multiple developers are progressing through clinical pipelines, with some submissions before the FDA. Oral therapy is not equivalent to subcutaneous treatment for all indications, but it provides a compliant pathway that does not depend on compounding.

• Continuity of care should be discussed with your prescriber before any therapy change
• Branded products may be available via manufacturer savings programs or insurance reauthorization
• Sudden discontinuation of GLP-1 therapy can be associated with weight regain; clinical guidance is essential
• Online sources promising compounded GLP-1 below branded pricing in mid-2026 are unreliable
• Any product not dispensed by a licensed pharmacy under a valid prescription is not a clinical product

Research-grade peptides exist for a defined purpose: in vitro and in vivo laboratory experimentation. They are not therapeutic products. They are not labeled, dosed, or quality-controlled for human administration. Substituting research-grade material for clinical care is unlawful, unsafe, and outside the scope of what ChemVerify or any responsible information source endorses.

• Read more: Medicare GLP-1 Bridge Program: $50/Month Coverage Starting July 2026 → https://www.chemverify.com/learn/medicare-glp1-bridge-program-50-month-coverage-july-2026
• Read more: FDA Tightens Compounding Rules for Peptides: What the 2026 Regulatory Shift Means → https://www.chemverify.com/learn/fda-tightens-compounding-rules-peptides-2026-regulatory-shift
• Read more: Orforglipron (Foundayo) FDA Approval: First Food-Free Oral GLP-1 → https://www.chemverify.com/learn/orforglipron-foundayo-fda-approval-oral-glp1
• Read more: Peptide Telehealth vs Research-Grade: Cost and Access Comparison 2026 → https://www.chemverify.com/learn/peptide-telehealth-vs-research-grade-2026-comparison